186 related articles for article (PubMed ID: 36171229)
1. Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.
El-Ghobashy NM; El-Sayed SM; Shehata IA; El-Ashmawy MB
Sci Rep; 2022 Sep; 12(1):16246. PubMed ID: 36171229
[TBL] [Abstract][Full Text] [Related]
2. Benzoxazole-appended piperidine derivatives as novel anticancer candidates against breast cancer.
AboulWafa OM; Daabees HMG; El-Said AH
Bioorg Chem; 2023 May; 134():106437. PubMed ID: 36842320
[TBL] [Abstract][Full Text] [Related]
3. Benzoxazole derivatives as new generation of anti-breast cancer agents.
Omar AME; AboulWafa OM; El-Shoukrofy MS; Amr ME
Bioorg Chem; 2020 Mar; 96():103593. PubMed ID: 32004897
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells.
Omar AME; AboulWafa OM; Amr ME; El-Shoukrofy MS
Bioorg Chem; 2021 Apr; 109():104752. PubMed ID: 33657444
[TBL] [Abstract][Full Text] [Related]
5. New Quinoxaline-Based Derivatives as PARP-1 Inhibitors: Design, Synthesis, Antiproliferative, and Computational Studies.
Syam YM; Anwar MM; Abd El-Karim SS; Elokely KM; Abdelwahed SH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956876
[TBL] [Abstract][Full Text] [Related]
6. In-vitro Anti-cancer assay and apoptotic cell pathway of newly synthesized benzoxazole-N-heterocyclic hybrids as potent tyrosine kinase inhibitors.
Desai S; Desai V; Shingade S
Bioorg Chem; 2020 Jan; 94():103382. PubMed ID: 31662214
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Preclinical Evaluation of Indole Triazole Conjugates as Microtubule Targeting Agents that are Effective against MCF-7 Breast Cancer Cell Lines.
Yele V; Pindiprolu SKSS; Sana S; Ramamurty DSVNM; Madasi JRK; Vadlamani S
Anticancer Agents Med Chem; 2021; 21(8):1047-1055. PubMed ID: 32981511
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, Anticancer Evaluation, and Molecular Docking Studies of Novel Benzoxazole Linked 1,3,4-Oxadiazoles.
Bujji S; Kumar EP; Sivan SK; Manjunatha DH; Subhashini NJP
Anticancer Agents Med Chem; 2022; 22(5):933-942. PubMed ID: 34229589
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological evaluation and molecular docking study of novel urea-based benzamide derivatives as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.
Lu G; Nie W; Xin M; Meng Y; Gu J; Miao H; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2022 Dec; 243():114790. PubMed ID: 36183505
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
Abdelgawad MA; Bakr RB; Omar HA
Bioorg Chem; 2017 Oct; 74():82-90. PubMed ID: 28772160
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel benzamide derivatives bearing benzamidophenyl and phenylacetamidophenyl scaffolds as potential antitumor agents via targeting PARP-1.
Lu G; Nie W; Xin M; Meng Y; Jiang J; Gu J; Cheng X; Chan ASC; Zou Y
Eur J Med Chem; 2023 May; 251():115243. PubMed ID: 36921527
[TBL] [Abstract][Full Text] [Related]
18. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship.
Chen M; Huang H; Wu K; Liu Y; Jiang L; Li Y; Tang G; Peng J; Cao X
Drug Dev Res; 2022 Feb; 83(1):55-63. PubMed ID: 34151456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
